林业发展局警告说,Wegovy与突如其来的视力丧失风险大大高于其他含硫酸盐药物有关联。 Wegovy linked to significantly higher risk of sudden vision loss vs. other semaglutide drugs, FDA warns.

与Ozempic和Rybelsus等其他硫酸盐药物相比,Wegovy(一种为减重而注射高剂量的硫酸盐)与突如其来的视力丧失风险(非遗传性前天缺血性眼科神经病(NAION))明显较高。 A new study links Wegovy, a high-dose semaglutide injection for weight loss, to a significantly higher risk of sudden vision loss—non-arteritic anterior ischemic optic neuropathy (NAION)—compared to other semaglutide drugs like Ozempic and Rybelsus. 研究人员分析了2017年至2024年超过3000万份FDA不良事件报告,发现Wegovy的NAION风险几乎是Ozempic的五倍,男性的风险是Ozempic的三倍以上. Analyzing over 30 million FDA adverse event reports from 2017 to 2024, researchers found Wegovy had nearly five times the NAION risk of Ozempic and more than three times higher risk in men. 较高的风险可能与Wegovy的注射形式、较高剂量和更快吸收有关,而Rybelsus(口述形式)则没有显示氮化物病例。 The higher risk may be tied to Wegovy’s injection form, higher dose, and faster absorption, while Rybelsus, an oral form, showed no NAION cases. 没有发现提尔泽胺增加风险. No increased risk was found with tirzepetide. 虽然Novo Nordisk坚持认为,没有因果关系得到证实,利益大于风险,但增加了安全警告。 Though Novo Nordisk maintains no causal link is proven and benefits outweigh risks, safety warnings have been added. 专家们呼吁开展进一步的研究,以澄清风险并提供指导。 Experts call for further research to clarify risks and guide prescribing.